Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer

摘要

BackgroundGoserelin plus aromatase inhibitors (AI) have already been used in male advanced breast cancer, but the cases that fulvestrantin male breast cancer are rare.